About EAM 2201

This analyze proposes that K2's substantial adverse outcome occurrence is because of, at the least partially, to distinctive JWH-018 metabolite action on the cannabinoid 1 receptor (CB1R), and indicates that metabolites of most prescription drugs, although not the carboxy metabolite, retain i